Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shire Plc's ADHD Amphetamine Wins British Backing-Reuters


Tuesday, 18 Dec 2012 12:00pm EST 

Reuters reported that Shire Plc's hyperactivity treatment Vyvanse will be available in Europe within months after Britain's drugs regulator backed the amphetamine based stimulant used to treat millions of U.S. students. The drug, lisdexamfetamine dimesylate, has a slow-release action that activates the amphetamine ingredient over the course of a day, helping levels of alertness and concentration in children with ADHD (attention deficit hyperactivity disorder). 

Company Quote

246.37
-4.87 -1.94%
3:58pm EDT